ALPHA COGNITION

A cholinesterase inhibitor is indicated for the treatment of mild to moderate dementia of AD. Zunveyl was designed to eliminate drug absorption in the GI tract and reduce the incidence of insomnia, potentially addressing certain tolerability issues and side effects caused by leading cholinesterase inhibitors. Galantamine, the active ingredient in Zunveyl, is believed to improve the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to affect cognition positively. Zunveyl is also being developed in combination with memantine to treat moderate to severe AD.